SCHEMBL4490615

SCHEMBL4490615

CCOC(=O)C1CCCC1N(C)C(=O)CC1=NS(=O)(=O)c2cc(NS(C)(=O)=O)ccc2N1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.33
MMP13 P45452 1/20 0.33
LMNA P02545 4/20 0.33
ALDH1A1 P00352 4/20 0.33
RECQL P46063 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 2/20 0.32
THRB P10828 1/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 3/20 0.31
GAA P10253 2/20 0.31
MAPK1 P28482 1/20 0.31
CYP3A4 P08684 2/20 0.31
POLB P06746 2/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
JAK1 P23458 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493109 0.92 MMP2 (0.33) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4481288 0.91 MMP2 (0.33) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4480672 0.90 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4486282 0.90 MAPT (0.33) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4489808 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL13712260 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL13712254 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL13712257 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4495276 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL
SCHEMBL4491594 0.88 MMP2 (0.31) MMP2MMP13LMNAALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS MMP2 4305/4885MMP13 3395/4885LMNA 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.